Physician profile
Peter Daniel Nicholas
NPI 1740714062
$5,779.80
in general payments reported to CMS, 2019-2025
23 companies · $1,746 in 2025
The $1,746 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.45 · 2020: $15.65 · 2021: $108 · 2022: $259 · 2023: $1,509 · 2024: $2,127 · 2025: $1,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,134 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,134.21 |
| Education | $247.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,114.77 | 2022-2025 | Evenity, Prolia, Tavneos |
| Astrazeneca Pharmaceuticals LP | $970.30 | 2022-2025 | Saphnelo |
| Abbvie INC. | $722.98 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $690.81 | 2022-2025 | |
| Janssen Biotech, INC. | $415.58 | 2022-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $322.90 | 2024-2025 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $258.40 | 2021-2023 | |
| Glaxosmithkline, LLC. | $254.82 | 2023-2025 | Benlysta |
| Lilly USA, LLC | $204.64 | 2023-2025 | Taltz |
| Alexion Pharmaceuticals, INC. | $147.31 | 2023-2025 | Strensiq, Ultomiris |
| Genentech USA, INC. | $89.01 | 2023-2025 | Actemra, Rituxan |
| Radius Health, INC. | $88.16 | 2023-2025 | Tymlos |
| Kyowa Kirin, INC. | $85.22 | 2023-2025 | Crysvita |
| Genzyme Corporation | $82.27 | 2024 | |
| Ani Pharmaceuticals, INC. | $78.36 | 2023-2025 | Purified Cortrophin Gel |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $73.95 | 2020-2024 | Orencia |
| Fresenius Kabi USA, LLC | $65.35 | 2025 | Adalimumab-Aacf |
| Pfizer INC. | $26.24 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $20.29 | 2023 | Opsumit |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $18.05 | 2024 | Arcalyst |
| Horizon Therapeutics Plc | $15.45 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $15.25 | 2023 | Iovera, Zilretta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Nicholas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.